Range Resources: Piper Sandler Maintains Neutral Rating, PT Down to $39 from $41
ByAinvest
Thursday, Aug 14, 2025 10:36 am ET1min read
PIPR--
Piper Sandler's revised PT reflects the company's performance and the broader market sentiment. Despite a 1.8% increase in shares owned by Charles Schwab Investment Management Inc. in the first quarter, the overall institutional ownership stands at 98.93%, indicating a significant interest from major investors [1].
Analysts have mixed opinions on Range Resources, with a consensus rating of "Hold" and an average price target of $43.37. Mizuho, for instance, has increased its price objective to $48.00, while UBS Group and Royal Bank of Canada have set their targets at $42.00 and $45.00, respectively [1].
Range Resources reported earnings per share (EPS) of $0.66 for the quarter, beating analyst estimates of $0.65. The company also announced a quarterly dividend of $0.09, representing a $0.36 annualized dividend and a dividend yield of 1.1% [1].
The company's focus on natural gas exploration and production in the Appalachian region has been a key driver of its performance. However, the recent delay in clinical trials by Vicarious Surgical Inc. (NYSE: RBOT), a company in the surgical robotics sector, has had a ripple effect on the broader market sentiment [2].
Investors should keep a close eye on Range Resources' future earnings reports and any strategic updates from the company. The lowered PT by Piper Sandler serves as a reminder of the potential risks and uncertainties in the energy sector, particularly in the face of fluctuating oil prices and geopolitical tensions.
References:
[1] https://www.marketbeat.com/instant-alerts/filing-range-resources-corporation-nyserrc-shares-purchased-by-charles-schwab-investment-management-inc-2025-08-13/
[2] https://za.investing.com/news/analyst-ratings/piper-sandler-lowers-vicarious-surgical-stock-price-target-on-delayed-clinical-use-93CH-3836983
RRC--
Range Resources: Piper Sandler Maintains Neutral Rating, PT Down to $39 from $41
In a recent update, Piper Sandler has maintained its neutral rating on Range Resources Corporation (NYSE: RRC) but has lowered its price target (PT) from $41 to $39. This adjustment comes following the company's second-quarter earnings report and the latest analyst ratings [1].Piper Sandler's revised PT reflects the company's performance and the broader market sentiment. Despite a 1.8% increase in shares owned by Charles Schwab Investment Management Inc. in the first quarter, the overall institutional ownership stands at 98.93%, indicating a significant interest from major investors [1].
Analysts have mixed opinions on Range Resources, with a consensus rating of "Hold" and an average price target of $43.37. Mizuho, for instance, has increased its price objective to $48.00, while UBS Group and Royal Bank of Canada have set their targets at $42.00 and $45.00, respectively [1].
Range Resources reported earnings per share (EPS) of $0.66 for the quarter, beating analyst estimates of $0.65. The company also announced a quarterly dividend of $0.09, representing a $0.36 annualized dividend and a dividend yield of 1.1% [1].
The company's focus on natural gas exploration and production in the Appalachian region has been a key driver of its performance. However, the recent delay in clinical trials by Vicarious Surgical Inc. (NYSE: RBOT), a company in the surgical robotics sector, has had a ripple effect on the broader market sentiment [2].
Investors should keep a close eye on Range Resources' future earnings reports and any strategic updates from the company. The lowered PT by Piper Sandler serves as a reminder of the potential risks and uncertainties in the energy sector, particularly in the face of fluctuating oil prices and geopolitical tensions.
References:
[1] https://www.marketbeat.com/instant-alerts/filing-range-resources-corporation-nyserrc-shares-purchased-by-charles-schwab-investment-management-inc-2025-08-13/
[2] https://za.investing.com/news/analyst-ratings/piper-sandler-lowers-vicarious-surgical-stock-price-target-on-delayed-clinical-use-93CH-3836983
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet